| Literature DB >> 20441516 |
Catherine A Blish1, Laura Sangaré, Bradley R Herrin, Barbra A Richardson, Grace John-Stewart, Judd L Walson.
Abstract
Albendazole treatment of individuals with human immunodeficiency virus type 1 (HIV-1) and Ascaris lumbricoides co-infection has led to significantly improved CD4(+) cell counts and a trend for lower plasma HIV-1 RNA levels in a previous randomized placebo-controlled trial. To define mechanisms by which deworming contributed to changes in markers of HIV-1 disease progression, plasma cytokine levels were evaluated. Albendazole treatment, compared with placebo, was associated with significantly decreased plasma interleukin (IL) 10 levels (P = .01)ot associated with significant changes in levels of IL-1beta, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-12p70, IL-13, interferon gamma, tumor necrosis factor alpha, or thymic stromal lymphopoietin. Treatment of A. lumbricoides co-infection may delay HIV-1 disease progression by reducing helminth-induced, IL-10-mediated immunosuppression.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20441516 PMCID: PMC2946624 DOI: 10.1086/652784
Source DB: PubMed Journal: J Infect Dis ISSN: 0022-1899 Impact factor: 5.226